Protocols · Longevity & Mitochondrial
GHK-Cu Anti-Aging & Skin Regeneration Protocol
Copper Tripeptide Complex | Skin Regeneration & Hair Restoration
Typical Dose
1-2 mg SC
3-5x/week; topical 1-2% AM/PM
Route
Subcutaneous / Topical
Dual-route delivery
Cycle
4wk load → 12wk+
Optional on/off cycling
Storage
Refrigerate 2-8°C
Protect from light; copper sensitive
Patient version available. Share ?view=patient with patients for the plain-language handout.
Overview
GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper II) is a naturally occurring tripeptide-copper complex whose plasma concentrations decline progressively from approximately 200 ng/mL in the third decade to ~80 ng/mL by the seventh. This protocol leverages systemic subcutaneous and topical delivery to restore tissue-level GHK-Cu activity for patients presenting with photoaged skin, impaired wound healing, androgenetic or telogen-pattern hair thinning, and early dermal atrophy.
The target patient is typically 35–70 years old with cosmetic and functional concerns related to skin laxity, fine lines, dyspigmentation, scarring (post-acne, surgical, or actinic), or scalp follicular miniaturization. Secondary candidates include patients in post-procedural recovery (laser, microneedling, surgical) seeking to accelerate dermal remodeling, and those with chronic wounds or radiation dermatitis under specialist oversight.
The stack combines two GHK-Cu concentrations to allow flexible systemic dosing (lower 50 mg vial for maintenance or sensitive patients; 100 mg vial for loading phases or larger surface-area topical compounding). Together, the regimen aims to upregulate dermal collagen I/III and decorin, modulate matrix metalloproteinase activity, stimulate angiogenesis, and exert antioxidant and anti-inflammatory effects at both cutaneous and systemic levels.
Key Benefits
Restores age-declining tripeptide-copper activity to drive collagen I/III synthesis, dermal remodeling, antioxidant defense, and follicular anagen prolongation across both skin and scalp.
Mechanism of Action
Copper-dependent modulation of >4,000 human genes — upregulating collagen, elastin, decorin, and SOD while suppressing TGF-β1 fibrotic signaling and TNF-α/IL-6 inflammation.
Molecular Information
Weight
340.4 Da (peptide) / ~403.9 Da (Cu complex)
Length
3 amino acids
Type
Tripeptide-copper(II) complex
Amino Acid Sequence
Gly-His-Lys :: Cu²⁺
* Naturally occurring; plasma levels decline from ~200 ng/mL (age 20s) to ~80 ng/mL (age 60s).
Pharmacokinetics
Research Indications
Photoaging & Skin QualityEFFECTIVE
Fine Lines & Texture
Controlled topical studies show reduction in rhytids and improved skin density vs vehicle at 12 weeks.
Dyspigmentation
Improvement in post-inflammatory hyperpigmentation and photodamage by week 8-12.
Dermal Thickening
Upregulates COL1A1/COL3A1, elastin, and decorin; measurable on ultrasound in responders.
Wound Healing & ScarringEFFECTIVE
Post-Procedural Recovery
Accelerates remodeling after laser, microneedling, and surgical procedures.
Scar Remodeling
Reduces atrophic and hypertrophic scar appearance via balanced MMP modulation.
Chronic Wounds
Encouraging but limited data in diabetic ulcers and radiation dermatitis.
Hair RestorationEMERGING
Androgenetic Thinning
Prolongs anagen phase and reduces 5α-reductase activity in some in vitro models.
Density Improvement
Visible density improvement in ~40-60% of clinical responders by week 12.
Shedding Reduction
Stabilization of telogen shedding typically by week 8.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Loading (Weeks 1-4) | 2 mg | 5x/week | SC evening |
| Maintenance (Weeks 5-12) | 1-2 mg | 3x/week | SC |
| Long-term (12wk+) | 1 mg | 2-3x/week | SC or topical-only |
| Topical Face | 1-2% cream/serum | AM & PM | Topical |
| Scalp Solution | 0.05-0.1% | Nightly | Topical |
| Post-Procedure | 2 mg + topical | Daily × 7-10 days | SC + topical |
Timing · SC dosing remains empirically derived — published human SC PK data are limited. Begin at the lower end and titrate. Avoid open wounds unless using sterile compounded formulation.
Peptide Interactions
- BPC-157— Complementary tissue repair and angiogenesis pathways.SYNERGISTIC
- TB-500— Pairs well for post-procedural and wound-healing protocols.SYNERGISTIC
- Epitalon— Longevity-stack compatible; no known interaction.COMPATIBLE
- Penicillamine— Copper chelator — mutually antagonistic.AVOID
- Trientine— Copper chelator; negates GHK-Cu activity.AVOID
- High-dose Zinc— May reduce copper bioavailability; balance ratios.MONITOR
- Melanotan II— Both affect pigmentation; watch for additive hyperpigmentation.MONITOR
- GHRP-2 / GHRP-6— No known interaction; commonly stacked for skin/recovery.COMPATIBLE
How to Reconstitute
- 1
Sanitize hands and work surface. Gather 100 mg GHK-Cu vial, 5 mL bacteriostatic water, alcohol swabs, and an insulin syringe.
- 2
Wipe rubber stoppers of both vials with alcohol and allow to air dry.
- 3
Draw 5 mL of bacteriostatic water into a sterile syringe.
- 4
Inject the BAC water slowly into the GHK-Cu vial, angling the needle so liquid runs down the inner wall — do not spray directly onto the powder.
- 5
Allow the powder to fully dissolve. Gently swirl — do not shake. The solution will be deep blue indicating copper coordination.
- 6
Final concentration: 100 mg / 5 mL = 20 mg/mL, so 0.1 mL of an insulin syringe = 2 mg.
- 7
Label the vial with reconstitution date and concentration.
- 8
Store reconstituted vial refrigerated (2-8°C), protected from light.
- 9
For SC injection: draw desired volume, pinch subcutaneous tissue (abdomen or thigh), insert at 45-90° and inject slowly.
- 10
For topical compounding: have pharmacy formulate at 1-2% in a stable base (avoid ascorbic acid or strong acids which destabilize the Cu complex).
- 11
Use reconstituted solution within 30 days.
Quality Indicators
Deep Blue Solution
Reconstituted solution should be a clear, deep blue color indicating intact Cu²⁺ coordination.
Pale or Colorless
Indicates inadequate copper loading or degraded peptide — do not use.
Precipitate or Cloudiness
Discard. May indicate contamination or incompatible diluent.
Stable Refrigerated
Maintains potency for ~30 days when refrigerated and protected from light.
What to Expect
Week 2-4: Improved hydration, surface texture, and subjective 'glow'.
Week 4-6: Reduced facial erythema and reactivity; faster bruise resolution.
Week 6-8: Measurable softening of fine lines and superficial rhytids.
Week 8: Hair shedding stabilizes; early vellus-to-terminal conversion possible.
Week 12: Visible firmness, elasticity, and scar improvement; dermal thickening on ultrasound in responders.
Week 12+: ~40-60% of hair patients show visible density improvement.
Possible transient blue-green discoloration of skin or fabrics from topical copper.
Non-responders to topical typically self-identify by week 6-8 — consider microneedling adjunct.
Side Effects & Safety
- Injection site erythema, pruritus, or transient bruising
- Mild stinging or burning with topical application
- Transient blue-green discoloration of skin or fabrics
- Headache or lightheadedness with higher SC doses (rare)
- Hyperpigmentation reported anecdotally at very high topical concentrations
- Possible flare in active autoimmune dermatologic disease
When to Stop & Call Provider
- Signs of copper toxicity: nausea, abdominal pain, jaundice
- Severe or persistent injection site reaction
- Allergic reaction (rash, swelling, difficulty breathing)
- Unexplained neurologic symptoms (tremor, ataxia)
- New or worsening pigmented lesions during therapy
- Discovery of pregnancy or active malignancy
References
Pickart L, Margolina A. — Regenerative and Protective Actions of GHK-Cu Peptide
Comprehensive review of GHK-Cu's modulation of >4,000 human genes relevant to tissue remodeling, antioxidant defense, and DNA repair pathways.
Leyden J, et al. — Skin Care Benefits of Copper Peptide Containing Facial Cream
Controlled trial demonstrating improvement in photoaged skin, fine lines, and skin density versus vehicle with topical GHK-Cu over 12 weeks.
Finkley MB, et al. — Copper Peptide and Wound Healing
Demonstrated accelerated healing of chronic diabetic ulcers with copper-peptide formulations versus standard care.
Pickart L. — The Human Tripeptide GHK and Tissue Remodeling
Foundational work documenting GHK-Cu's upregulation of COL1A1/COL3A1, decorin, and elastin synthesis in dermal fibroblasts.